Table 6.
Risk factors for the development of PCP in transplant recipients
| Parameters | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| With PCP | Without PCP | P | OR | CI | P | |
| Preoperative | ||||||
| Sex (male/female) | 9/1 | 27/3 | 1.000 | |||
| Age | 55.50±13.00 | 55.93±10.57 | 0.916 | |||
| Primary disease (benign) | 3 | 9 | 1.000 | |||
| Child score | 7.90±2.73 | 8.23±2.84 | 0.747 | |||
| MELD score | 14.90±9.77 | 15.50±10.60 | 0.875 | |||
| BMI | 24.51±3.09 | 24.70±3.50 | 0.876 | |||
| Diabetes | 2 | 9 | 0.696 | |||
| Smoking | 3 | 10 | 1.000 | |||
| Drinking | 2 | 10 | 0.693 | |||
| Heart disease | 1 | 2 | 1.000 | |||
| Respiratory disease | 1 | 1 | 0.442 | |||
| Albumin (g/L) | 37.08±6.60 | 35.82±7.03 | 0.620 | |||
| Creatinine (µmol/L) | 72.72±19.82 | 97.61±92.67 | 0.662* | |||
| Bilirubin (µmol/L) | 234.43±348.05 | 148.97±221.42 | 0.888* | |||
| INR | 1.38±0.55 | 1.38±0.56 | 0.978 | |||
| Lymphocyte count (/L) | 1.24±0.68 | 1.11±0.68 | 0.626 | |||
| Lymphocyte percentage (%) | 22.54±10.13 | 21.98±8.80 | 0.868 | |||
| Operative | ||||||
| Operating time (min) | 549.50±219.15 | 500.13±111.00 | 0.354 | |||
| Warm ischemia time (min) | 2.70±1.06 | 2.57±0.86 | 0.802* | |||
| Cold storage time (h) | 7.20±1.03 | 7.43±0.94 | 0.376* | |||
| Bleeding (ml) | 740.00±245.85 | 790.00±326.26 | 0.660 | |||
| Transfusion (ml) | 600.00±432.05 | 693.33±734.82 | 0.707 | |||
| Surgical type (piggyback) | 10 | 29 | 1.000 | |||
| Anhepatic phase (ml) | 58.80±30.33 | 74.00±36.72 | 0.246 | |||
| Postoperative | ||||||
| Acute rejection | 3 | 3 | 0.153 | |||
| CMV | 2 | 4 | 0.629 | |||
| Respiratory infection | 4 | 7 | 0.418 | |||
| Bile leak | 0 | 1 | 1.000 | |||
| Delayed graft function | 1 | 0 | 0.250 | |||
| Bleeding | 0 | 0 | - | |||
| Abdominal infection | 2 | 4 | 0.629 | |||
| Immunosuppressants | 0.906 | |||||
| Tacrolimus | 9 | 28 | ||||
| Sirolimus | 4 | 9 | ||||
| MMF | 4 | 14 | ||||
| Cyclosporin A | 1 | 2 | ||||
| Prednisone | 1 | 1 | ||||
| Tacrolimus concentration (ng/ml) | 7.57±2.62 | 5.52±2.14 | 0.023 | 0.770 | 0.435-1.366 | 0.372 |
| ICU stay time (h) | 91.90±34.92 | 125.23±70.44 | 0.161 | |||
| #CD3+ T-cell counts (/µL) | 306.81±222.40 | 655.00±323.44 | 0.003 | 0.996 | 0.953-1.041 | 0.854 |
| #CD3+ T-cell percentage (%) | 62.53±16.41 | 67.58±13.99 | 0.349 | |||
| #CD4+ T-cell counts (/µL) | 168.15±152.02 | 365.01±220.06 | 0.012 | 1.004 | 0.955-1.056 | 0.872 |
| #CD4+ T-cell percentage (%) | 31.64±11.42 | 37.28±11.60 | 0.189 | |||
| #CD8+ T-cell counts (/µL) | 132.32±85.59 | 261.34±175.18 | 0.033 | 1.009 | 0.963-1.056 | 0.710 |
| #CD8+ T-cell percentage (%) | 29.82±15.61 | 27.66±15.28 | 0.701 | |||
| #CD19+ B-cell counts (/µL) | 48.09±39.11 | 164.68±89.50 | 0.000 | 1.028 | 1.000-1.057 | 0.049 |
| #CD19+ B-cell percentage (%) | 12.34±10.03 | 18.54±10.63 | 0.114 | |||
PCP, Pneumocystis pneumonia; OR, odds ratio; CI, 95% confidence interval; MELD, model for end-stage liver disease; BMI, body mass index; INR, international normalized ratio; CMV, cytomegalovirus; MMF, Mycophenolate mofetil; ICU, intensive care unit.
*
Mann-Whitney U was used.
#
PCP cases tested right after diagnosis; controls tested following the same period as PCP patients.